Clinical Efficacy of Cilostazol combined with Prostaglandin E1 in the treatment of Early Type 2 Diabetic Nephropathy and its Effects on Serum CysC beta 2-MG and Urinary Protein
Abstract：Objective: To analyze the clinical curative effect of cilostazol combined with prostaglandin E1 on early type 2 diabetic nephropathy and the influence on serum cystatin C (CysC), β2-microglobulin (β2-MG) and urine protein (ALB). Methods: A total of 90 patients with early type 2 diabetic nephropathy who were admitted to the hospital during the period from May 2016 to May 2018 were selected as subjects. They were randomly divided into the observation group and the control group, 45 cases in each group. The control group was treated with cilostazol and other conventional drugs. On this basis, the observation group was treated with prostaglandin E1. The treatment response rate, levels of serum CysC, β2-MG and glycosylated hemoglobin (HbA1c), renal function indexes [ALB, serum creatinine (Scr), blood urea nitrogen (BUN)] before and after treatment and adverse reactions were compared between the two groups. Results: The treatment response rate in the observation group was significantly higher than that in the control group (93.33% vs 75.56%) (P<0.05). The decrease oflevels of serum CysC, β2-MG and HbA1c, ALB, Scr and BUN in the observation group was significantly larger than thatin the control group after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (13.33% vs 8.88%) (P>0.05). Conclusion: The treatment of early type 2 diabetic nephropathy patients with cilostazol combined with prostaglandin E1 can significantly improve the clinical efficacy, improve the serum CysC, beta 2-MG and renal function, and is safe and reliable, which is worthy of clinical promotion and practice.
2019, Vol. 25 
冀公网安备13080202000677号